Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939339 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6943333 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6939693 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6939699 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6941788 | 0.87 | ALDH1A1 (0.63) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL7563244 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6944321 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6944324 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL7076006 | 0.84 | MAPT (0.61) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL6939398 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPTPOLBHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | ALDH1A1 253/4885MAPT 4706/4885POLB 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.